Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBT (2023 - 2025)

Historic EBT for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.

  • Mereo BioPharma's EBT rose 5317.65% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 932.43%. This contributed to the annual value of -$43.3 million for FY2024, which is 4418.63% down from last year.
  • Mereo BioPharma's EBT amounted to -$7.0 million in Q3 2025, which was up 5317.65% from -$14.6 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year EBT high stood at -$1.8 million for Q2 2023, and its period low was -$15.0 million during Q3 2024.
  • Over the past 3 years, Mereo BioPharma's median EBT value was -$9.6 million (recorded in 2023), while the average stood at -$9.8 million.
  • In the last 5 years, Mereo BioPharma's EBT plummeted by 59988.58% in 2024 and then skyrocketed by 5317.65% in 2025.
  • Quarter analysis of 3 years shows Mereo BioPharma's EBT stood at -$9.6 million in 2023, then increased by 26.92% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
  • Its EBT was -$7.0 million in Q3 2025, compared to -$14.6 million in Q2 2025 and -$12.9 million in Q1 2025.